Abstract
Oral Cancer (OC) is a serious and growing problem which constitutes a huge burden on people in more and less economically developed countries alike. The scenario is clearly depicted from the increase in the expected number of new cases in the US diagnosed with OC from 49,670 people in 2016, to 49,750 cases in 2017. The situation is even more alarming in India, with 75,000 to 80,000 new cases being reported every year, thus making it the OC capital of the world. Leukoplakia, erythroplakia, oral lichen planus, oral submucous fibrosis, discoid lupus erythmatosus, hereditary disorders such as dyskeratosis congenital and epidermolisys bullosa are highlighted by WHO expert working group as the predisposing factors increasing the risk of OC. Consumption of tobacco and alcohol, genetic factors, and human papilloma virus are assigned as the factors contributing to the aetiology of OC. On the other hand, pathogenesis of OC involves not only apoptosis but also pain, inflammation and oxidative stress. Inspite of current treatment options (surgery, radiotherapy, and chemotherapy), OC is often associated with recurrence and formation of secondary primary tumours resulting in poor overall survival rates (∼50%). The intervention of nano technology-based drug delivery systems as therapeutics for cancers is often viewed as a cutting edge for technologists. Though ample literature on the usefulness of nano-coutured cancer therapeutics, rarely any product is in pipeline. Yet, despite all the hype about nanotechnology, there are few ongoing trials. This review discusses the current and future trends of nano-based drug delivery for the treatment of OC.
Keywords: Oral cancer, epidemiology, pathogenesis, chemotherapy, nanotechnology, radiotherapy.
Graphical Abstract
[1]
Giannola LI, De Caro V, Giandalia G, et al. 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa. Curr Drug Deliv 2010; 7: 109-17.
[2]
Anaya JM, Ramirez-Santana C, Alzate MA, et al. The Autoimmune Ecology. Front Immunol 2016; 7: 139.
[4]
Gupta B, Ariyawardana A, Johnson NW. Oral cancer in India continues in epidemic proportions: evidence base and policy initiatives. Int Dent J 2013; 63: 12-25.
[5]
Swaminathan R, Ranganathan R, Viswanathan S. Lack of active follow-up of cancer patients in Chennai, India: Implications for population-based survival estimates. Bull World Health Organ 2008; 86: 509-15.
[6]
Sankaranarayan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 1998; 18: 4779-86.
[7]
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132(5): 1133-45.
[8]
Peterson PE. Strengthening the prevention of oral cancer: the WHO perspective. Community Dent Oral Epidemiol 2005; 33: 397-9.
[9]
Vartanian JG. Socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132: 32-5.
[10]
Ganesh R, John J, Saravanan S. Socio demographic profile of oral cancer patients residing in Tamil Nadu - A hospital based study. Indian J Cancer 2013; 50(1): 9-13.
[11]
Ram H, Sarkar J, Kumar H, et al. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg 2011; 10(2): 132-7.
[12]
Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: Etiology and risk factors: A review. J Can Res Ther 2016; 12: 458-63.
[13]
Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14(2): 467-75.
[14]
Krishna A, Singh S, Kumar V, Pal US. Molecular concept in human oral cancer. Natl J Maxillofac Surg 2015; 6(1): 9-15.
[15]
Shukla A. Potentially malignant disorders of the oral cavity: A clinical study. Indian J Otolaryngol Head Neck Surg 2014; 66(1): 79-85.
[16]
Prout MN, Sidari JN, Witzburg RA. Head and neck cancer screening among 4,611 tobacco users older than 40 years. Otolaryngol Head Neck Surg 1997; 116: 201-8.
[17]
Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. J Pathol 1994; 145(5): 1023-9.
[18]
Bobik A, Campbell JH. Vascular-derived growth factors: cell biology, pathophysiology, and pharmacology. Pharmacol Rev 1993; 45: 1-42.
[19]
Sawlani K, Kumari N, Mishra AK, Agrawal U. Oral cancer prevalence in a tertiary care hospital in India. J Fam Med Community Health 2014; 1(4): 1022-7.
[20]
Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin North Am 2008; 52(1): 1-17.
[21]
Kumar P, Dupare R, Prince Kumar P, et al. Imperative role of early diagnosis in precancerous lesions: Oldideas, new findings, yet more questions. Clin Cancer Investig J 2012; 1: 184-9.
[22]
Divya VC, Sathasivasubramanian S. Estimation of serum and salivary immunoglobulin G and immunoglobulin A in oral pre-cancer: A study in oral submucous fibrosis and oral lichen planus. J Nat Sci Biol Med 2014; 5(1): 90-4.
[23]
Khalam SA, Kumar S, Zacariah RK, Kurien NM, Raj P. Oral submucous fibrosis: A clinical review. Madridge J Dent Oral Surg 2017; 2(1): 26-8.
[24]
Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S. Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 2006; 42(6): 561-8.
[26]
Messadi DV. Diagnostic aids for detection of oral precancerous conditions. Int J Oral Sci 2013; 5: 59-65.
[27]
Blot WJ, McLaughlin JK, Winn D, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7.
[28]
Cogliano V, Straif K, Baan R, Grosse Secretan B, El Ghissassi F. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol 2004; 5: 708.
[29]
Shaib WL, Assi R, Shamseddine A, et al. Appendiceal Mucinous Neoplasms: Diagnosis and Management [published correction appears in Oncologist. Oncologist 2017; 22(9): 1107-16.
[30]
Institute of Medicine (US) Committee on Cancer Control in Lowand
Middle-Income Countries; Sloan FA, Gelband H, editors. Cancer
Control Opportunities in Low- and Middle-Income Countries.
Washington (DC): National Academies Press (US) 2007: 2.
[31]
Green CE, Liu T, Montel V, et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS One 2009; 4(8)e6713
[32]
Tokunaga T, Oshika Y, Abe Y, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998; 77(6): 998-1002.
[33]
Jedinak A, Dudhgaonkar S, Sliva D. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 2010; 215(3): 242-9.
[34]
Zins K, Abraha D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007; 67(3): 1038-45.
[35]
Wang D, Wang H, Brown J, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203(4): 941-51.
[36]
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30(7): 1073-81.
[37]
Del Prete A, Allavena P, Santoro G, et al. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb) 2011; 21(3): 264-75.
[38]
Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park) 2011; 25(5): 400-10.
[39]
Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 2004; 40(2): 120-30.
[40]
Li TJ, Cui J. COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma. Asian Pac J Trop Biomed 2013; 6(8): 640-3.
[41]
Pontes H, Pontes FS, Fonseca FP, et al. Nuclear factor kappa B and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol 2013; 17(1): 45-50.
[42]
Mauro A. Mauro1 A, Lipari L, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in normal and pathological human oral mucosa. Folia Histochem Cytobiol 2010; 48(4): 555-63.
[43]
Yuan-Hua Xu, Zheng-Li Li, Sheng-Feng Qiu. IFN-γ Induces Gastric Cancer Cell Proliferation and Metastasis Through Upregulation of Integrin β3-Mediated NF-κB Signaling. Transl Oncol 2018; 11(1): 182-92.
[44]
Rao SK, Pavicevic Z, Du Z. Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 2010; 285(42): 32512-21.
[45]
Huang SH, O’Sullivan B. Oral cancer: Current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal 2013; 18(2): e233-40.
[46]
Hsu S, Singh B, Schuster G. Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and preven-tion. Oral Oncol 2004; 40: 461-73.
[47]
Vermorken JB, Remenar E, Herpen C, Gorlia T. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357(17): 1695-704.
[48]
Marcazzana S, Varonib EM, Blancoa E, Lodib G, Ferrari M. Nanomedicine, an emerging therapeutic strategy for oral cancer therapy. Oral Oncol 2018; 76: 1-7.
[49]
Wang C, Liu XQ, Hou JS, Wang JN, Huang HZ. Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res 2016; 19: 25-33.
[50]
Wang Z-Q, Liu K, Huo Z-J, et al. A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy. J Nanobiotechnology 2015; 13: 63.
[51]
Capoor MR, Bhowmik KT. Cytotoxic drug dispersal, cytotoxic safety, and cytotoxic waste management: practices and proposed india-specific guidelines. Indian J Med Paediatr Oncol 2017; 38(2): 190-7.
[52]
Tanaka Y, Baba T, Tagawa K, Waki R, Nagata S. Prediction of oral absorption of low-solubility drugs by using rat simulated gastrointestinal fluids: the importance of regional differences in membrane permeability and solubility. J Pharm Pharm Sci 2014; 17(1): 106-20.
[53]
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 2015; 200: 138-57.
[54]
Harrington KJ, Lewanski C, Northcote AD, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 2001; 37: 2015-22.
[55]
Alok A, Panat S, Aggarwal A, Upadhyay N, Agarwal N, Kishore M. Nanotechnology: A boon in oral cancer diagnosis and therapeutics. SRM J Res Dent Sci 2013; 4(4): 154-60.
[56]
Shoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanotechnology 2007; 3: 20-31.
[57]
Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today 2010; 15: 842-50.
[58]
Mousa SA, Bharali DJ. Nanotechnology-based detection and targeted therapy in cancer: Nano-Bio paradigms and applications. Cancers 2011; 3: 2888-03.
[59]
Eifer AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. In: Hurst SJ, editor.Biomedical Nanotechnology: Methods and Protocols. New York: Humana Press 2011; pp. 235-8.
[60]
Calixt G, Bernegossi J, Fonseca-Santos B, Chorilli M. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine 2014; 9: 3719-35.
[61]
Bobo D, Robinson KJ, Islam J. Nanoparticle-based medicines: A review of fda-approved materials and clinical trials to date. Pharm Res 2016; 33: 2373.
[62]
Shah JP, Gil Z. Current concepts in management of oral cancer--surgery. Oral Oncol 2009; 45(4-5): 394-401.
[63]
Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Natl Rev 2003; 3: 330-8.
[64]
Pendleton KP, Grandis JR. Cisplatin-based chemotherapy options for recurrent and/or metastatic squamous cell cancer of the head and neck. Clin Med Insights Ther 2013; 2013(5)
[http://dx.doi.org/10.4137/ CMT.S10409]
[http://dx.doi.org/10.4137/ CMT.S10409]
[65]
Zhao H, Feng H, Liu D, et al. Self-assembling monomeric nucleoside molecular nanoparticles loaded with 5-FU enhancing therapeutic efficacy against oral cancer. ACS Nano 2015; 9: 9638-51.
[66]
Bhavana SM, Lakshmi CR. Oral Oncoprevention by phytochemicals - a systematic review disclosing the therapeutic dilemma. Adv Pharm Bull 2014; 4(Suppl. 1): 413-20.
[68]
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 2008; 13: 472-82.
[69]
Bharalia DJ, Mousaa SA. Emerging nanomedicines for early cancer detection and improved treatment. Current perspective and future promise. Pharmacol Ther 2010; 128(2): 324-35.
[70]
Reddy RS, Dathar S. Nano drug delivery in oral cancer therapy: An emerging avenue to unveil. J med Radiol Pathol Surg 2015; 1: 17-22.
[71]
Damascelli B, Patelli GL, Lanocita R. Tolla GDA novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol 2003; 181(1): 253-60.
[72]
Sulfikkarali N, Krishnakumar N, Manoharan S, Nirmal RM. Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12- dimethylbenz(a)anthracene induced experimental oral carcinogenesis. Pathol Oncol Res 2013; 19(2): 287-96.
[73]
Abbasi MM, Monfaredan A, Hamishehkar H, Seidi K, Jahanban Esfahlan R. Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: oral and IV modalities. Asian Pac J Cancer Prev 2014; 15(15): 6227-32.
[74]
Endo K, Ueno T, Kondo S, Wakisaka N, Murono S. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci 2013; 104(3): 369-74.
[75]
Desai KGH. Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer. J Biomed Mater Res Part B 2018; 106B: 1383-413.
[76]
Mishra A, Kumar R, Tyagi A, Kohaar I. Curcumin modulates cellular AP-1, NF-kB, and HPV16 E6 proteins in oral cancer. Ecancermedicalscience 2015; 9: 1-12.
[77]
Lee AY, Fan CC, Chen YA, Cheng CW. Curcumin inhibits invasiveness and epithelial-mesenchymal transition in oral squamous cell carcinoma through reducing matrix metalloproteinase 2, 9 and modulating p53-e-cadherin pathway. Integr Cancer Ther 2015; 14(5): 484-90.
[78]
Nejad M, Takahashi H, Hosseini H, Watanabe A. Acute effects of sono-activated photocatalytic titanium dioxide nanoparticles on oral squamous cell carcinoma. Ultrason Sonochem 2016; 32: 95-101.
[79]
Mazzarino L, Loch-Neckel G, Bubniak S, et al. Curcumin-loaded chitosan-coated nanoparticles as a new approach for the local treatment of oral cavity. Cancer J Nanosci Nanotech 2015; 15: 781-91.
[80]
Satapathy SR, Siddharth S, Das D, Nayak A, Kundu CN. Enhancement of cytotoxicity and inhibition of angiogenesis in oral cancer stem cells by a hybrid nanoparticle of bioactive quinacrine and silver: Implication of base excision repair cascade. Mol Pharm 2015; 12(11): 4011-25.
[81]
Arulmozhi V, Pandian K, Mirunalini S. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB). Colloids Surf B Biointerfaces 2013; 110: 313-20.
[82]
Wang A, Li S. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect. BMC Biotechnol 2008; 8: 46.
[83]
Dineshkumar B, Krishnakumar K, Bhatt AR, John A. Solid lipid nanoparticles: investigation in cancer cell lines - a review. Curr Res Drug Target 2012; 2(1): 1-3.
[84]
Ahmad J, Amin S, Rahman M. Solid matrix based lipidic nanoparticles in oral cancer chemotherapy: applications and pharmacokinetics. Curr Drug Metab 2015; 16(8): 633-44.
[85]
Holpuch AS, Hummel GJ, Tong M. Nanoparticles for local drug delivery to the oral mucosa: Proof of principle studies. Pharm Res 2010; 27: 1224-36.
[86]
Mendoza E, Preat A, Mollinedo V. BlancoPrieto F. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release 2011; 156: 421-6.
[87]
Ventola MS. Progress in Nanomedicine: Approved and Investigational Nanodrugs. Pharm Ther 2017; 42(12): 742-55.
[88]
Sanad RA. Lipid nanoparticles (slns and nlcs): wide range of application from cosmetics to cancer chemotherapy. J Drug Res Egypt 2014; 35(1): 73-9.
[89]
Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. J Pharm Sci 2011; 43(3): 174-9.
[90]
Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine 2013; 8(9): 1-32.
[91]
Longo JPF, Muehlmann LA. Effects of photodynamic therapy mediated by liposomal aluminum-phthalocyanine chloride on chemically induced tongue tumors. Chemotherapy 2012; 1: 1-4.
[92]
Zhang F, Jin B, Dong X, Xu X. Development and in vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. Oncol Lett 2018; 15(2): 2541-9.
[93]
Vishnubhakthula S, Elupula R, Durán-Lara EF. Recent advances in hydrogel-based drug delivery for melanoma cancer therapy: a mini review. J Drug Deliv 2017; 20177275985
[94]
Ruel-Gariépy E, Shive M, Bichara A, et al. A thermosensitive chitosanbased hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm 2004; 57(1): 53-63.
[95]
Li J, Gong C, Feng X, Zhou X. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One 2012; 7(4): 1-8.
[96]
Kumar NK, Gurushankar K, Gohulkumar M, Prasad NR. Synthesis, characterization and in vitro anti-cancer evaluation of hesperetin-loaded nanoparticles in human oral carcinoma (KB) cells. Adv Nat Sci Na nosci. Nanotechnology 2013; 5: 1-10.
Article Metrics
72
11